Total Funding
57
61
Total FundingDebt Financing raised
Growth Score
-3 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
50244
Sollis Therapeutics is a pharmaceutical company developing non-opioid analgesic solutions.
- Bryan Jones: COOPast Role: Sorrento Therapeutics, Vice President Operations
Alex Dinello: President & CEOPast Role: Kyphon, Vice President, Research&Development
About the Company
Sollis Therapeutics is a clinical-stage specialty pharmaceutical company developing novel non-steroid, non-opioid analgesics. Sollis’ first product is an extended-release combination analgesic and anti-inflammatory drug designed for local delivery for the treatment of sciatica and other neuropathic pain syndromes.
The company was founded in 2017
and is headquartered in Columbus, Ohio.
